Back to discover
Disease

Meningitis

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHMeningitis
3
Publications
19
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)
Results expected Q3 20262026-06-24
Upcoming trial readoutHigh impact
Platform Trial For Cryptococcal Meningitis
Results expected Q2 20322026-06-22
Clinical Milestones7View
Results posted 1
Results expected 4
Recently completed 2
Activity timeline7

Clinical trials

16 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

Platform Trial For Cryptococcal Meningitis

Phase 2/3 · Recruiting · University of Minnesota

Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons

Phase 2/3 · Recruiting · Makerere University

A Phase 4, Single-arm, Open-label, Multi-center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine MenB+OMV NZ When Administered to Healthy Infants From 2 Months of Age in the Republic of Korea

Phase 4 · Active, not recruiting · GlaxoSmithKline

An Investigator-initiated, Single-center Academic Study in Healthy Transgender and Cisgender Persons Aged Between 18 and 50 Years to Investigate Gender and Sex Differences in Immune Responses to Meningococcal Serogroup B Vaccination

Phase 4 · Recruiting · University Ghent

Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)

Phase 3 · Recruiting · ANRS, Emerging Infectious Diseases

Phase IV Clinical Trial of Immunogenicity of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 6 to 23 Months

Phase 4 · Active, not recruiting · CanSino Biologics Inc.
Recently completed

A Randomized, Blinded, Comparable Vaccine-controlled Phase IIIb Clinical Trial to Evaluate the Safety and Immunogenicity of Meningococcal Polysaccharide Conjugate Vaccine, Group ACYW135 (CRM197 Vector), in a 4 to 6 Year-old Population

Phase 3 · Completed · CanSino Biologics Inc.

A Phase IIIB, Randomized, Controlled, Observer-blind Study to Evaluate Safety and Immunogenicity of GSK's Meningococcal ABCWY Vaccine When Administered in Healthy Adolescents and Adults, Previously Primed With Meningococcal ACWY Vaccine

Phase 3 · Completed · GlaxoSmithKline

A Phase 3 Trial to Evaluate the Safety, Immunogenicity, and Non-Interference With Concomitant Routine Vaccines, of a Meningococcal Serogroup ACYWX Conjugate Vaccine (NmCV-5) in Comparison With MenACWY-TT Conjugate Vaccine in Healthy Malian Infants

Phase 3 · Completed · Emory University

A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype

Phase 3 · Completed · Oxford University Clinical Research Unit, Vietnam

A Phase IV Randomized, Observer-blind, Controlled Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine as Compared to Sanofi Pasteur Menactra® Vaccine in Healthy Subjects Aged 2-10 Years

Phase 4 · Completed · Walvax Biotechnology Co., Ltd.

Phase 3, Observer-blind, Randomized, Active Controlled Trial to Assess the Safety of an Investigational Meningococcal Serogroups ACYWX Conjugate Vaccine (NmCV-5) and Compare Its Immunogenicity to a Licensed Meningococcal Serogroups ACYW Conjugate Vaccine (Menactra®), in Healthy Subjects 2 to 29 Years of Age

Phase 3 · Completed · Serum Institute of India Pvt. Ltd.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182024
Major themes5
  • Global Burden of Disease2
  • Global Health1
  • High-Throughput Nucleotide Sequencing1
  • Meningitis1
  • Metagenomics1
Leading journals2
  • The Lancet. Neurology2
  • The Journal of infection1
Leading researchers8
  • Chen W1
  • Cui L1
  • Du J1
  • Huan X1
  • Liu G1
  • Lv Y1
  • Tian F1
  • Wu Y1
Affiliations (unnormalised)4
  • Beijing Fengtai Youanmen Hospital1
  • Beijing Shijitan Hospital1
  • the First Medical Center of People's Liberation Army General Hospital1
  • Xuanwu Hospital1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)

Identifiers
MeSHMeningitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.